Clinical trials: Phase 2
Obesity, Overweight
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- ACCESS II (NCT06703021)
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Diabetes Mellitus, Type 2, Hypertriglyceridemia
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
The design of the Phase 2 clinical trial includes the following elements: Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs.
- Conditions
- Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05464784
- Testing
- MN-001
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MediciNova
Hidradenitis Suppurativa
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT03607487
- Testing
- INCB054707
- Where
- 13 sites in Canada, Denmark and 1 more
- Volunteers
- 35 people
- Sponsor
- Incyte Corporation
Lymphoma, Malignant, Advanced Solid Neoplasms
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.
- Trial name
- NCT03359733
- Testing
- TAK-659
- Where
- 3 sites in United States
- Sponsor
- Calithera Biosciences, Inc
HIV-1-infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This is a Phase II, randomized, open-label, multi-center, active-controlled study to assess the safety, tolerability, and efficacy of UB-421 administered as an add-on to the standard ART in ART-treated HIV-1 subjects with stably…
- Trial name
- HIV-1 (NCT04404049)
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Volunteers
- 39 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Solid Tumor
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, first-in-human study of IBI129. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI129, plan to enroll 22~180 subjects, and a phase 2 to explore efficacy…
- Trial name
- NCT05991349
- Testing
- IBI129
- Where
- 7 sites in Australia, China
- Volunteers
- 36 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
COVID
Niclosamide In Moderate COVID-19
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
- Trial name
- NCT04436458
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
Metastatic Breast Cancer
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
The purpose of this study is to determine whether IMC-A12 offers increased progression-free survival (PFS) associated with IMC-A12 monotherapy and IMC-A12 in combination with an antiestrogen therapy in patients with hormone…
- Trial name
- NCT00728949
- Testing
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Eli Lilly and Company
Chronic Hepatitis B
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects
- Trial name
- NCT05561530
- Testing
- ALG-125755
- Where
- 4 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Platinum-resistant Ovarian Cancer
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression.
- Trial name
- PROFECTA-II (NCT04374630)
- Testing
- Paclitaxel, Afuresertib
- Where
- 47 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Laekna Limited
Acute Ischemic Stroke
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1.
- Trial name
- ORION (NCT06990867)
- Testing
- JX10
- Where
- 104 sites in United States, Belgium and 19 more
- Volunteers
- 740 people
- Sponsor
- Corxel Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- Trial name
- HM-TRIA-201 (NCT04505436)
- Testing
- HM15211
- Where
- 60 sites in United States, South Korea
- Volunteers
- 215 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Meningococcal Disease
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
- Trial name
- NCT01000311
- Testing
- MenACWY-CRM, DTaP-IPV/Hib, HBV
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Virus
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated…
- Trial name
- NCT05127434
- Testing
- mRNA-1345
- Where
- 269 sites in United States, Argentina and 21 more
- Volunteers
- 36,814 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Prostatic Neoplasms
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
- Trial name
- NCT02381236
- Testing
- G-202
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GenSpera, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Trial name
- SYNERGY-101 (NCT05098132)
- Testing
- STK-012, pembrolizumab KEYTRUDA®, pemetrexed
- Where
- 47 sites in United States, Georgia and 2 more
- Volunteers
- 364 people
- Sponsor
- Synthekine
Healthy
A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase 1, singlecenter study to evaluate bioequivalence after administration of L04RD1 or administration of L04TD2 in healthy volunteers.
- Trial name
- NCT05581693
- Testing
- L04RD1, L04TD2
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Celltrion
Autistic Disorder
Field Test of Motivity.Net Software for Data Collection During Behavioral Interventions
This is a study funded by a Phase II SBIR to build and test the feasibility of a new software prototype for delivering evidence-based behavioral therapy treatment for autism.
- Trial name
- NCT03919721
- Testing
- Applied Behavioral Analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Experiad LLC
Advanced Melanoma
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with…
- Trial name
- NCT05529316
- Testing
- Botensilimab, Balstilimab
- Where
- 51 sites in United States, Belgium and 8 more
- Volunteers
- 150 people
- Sponsor
- Agenus Inc.
Non-small Cell Lung Cancer
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the benefit of adding suramin at a non-cytotoxic dose to carboplatin and docetaxel regimen in the treatment of chemo-naïve patients with non-small cell lung cancer.
- Trial name
- NCT01038752
- Testing
- Suramin Drug:Docetaxel Drug: Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Optimum Therapeutics, LLC